A judge ruled that three Republican-led states could proceed with their lawsuit to limit the availability of mifepristone abortion pills.
U.S. District Court Judge Matthew Kacsmaryk, in Amarillo (Texas), ruled that Idaho Missouri, and Kansas could continue their lawsuit against the U.S. Food and Drug Administration at his court. Last year, they joined a suit originally brought by doctors and anti-abortion organizations.
The original plaintiffs dropped the case after the U.S. Supreme Court ruled that they lacked legal standing to challenge FDA regulation of mifepristone.
The FDA argued the claims of the states should be dismissed, as the original plaintiffs were no longer present and had no connection with Kacsmaryk’s court.
Since 2000, the FDA has approved Mifepristone for use in conjunction with misoprostol to terminate a pregnancy. In the United States, medication abortion accounts for most abortions.
The newly formed Texas Alliance for Hippocratic Medicine, along with other abortion opponents, sued in 2022 to remove mifepristone from the market. They won the order in April 2023 from Kacsmaryk, granting their request. However, the 5th U.S. Circuit Court of Appeals reversed the decision, finding that it was too late for them to contest the original approval.
The 5th Circuit found, however, that the FDA acted illegally by loosening the restrictions on this drug in 2016. This included approving its use for the first 10 weeks, instead of seven, as well as allowing it to be prescribed via telemedicine and sent by mail.
The Supreme Court ruled that the plaintiffs did not have standing to appeal because the FDA’s actions had not harmed them. It didn’t even address the merits.
The FDA has not yet appealed the Kacsmaryk or 5th Circuit orders, so mifepristone is still available.
They have claimed that they have standing to bring a lawsuit because their Medicaid insurance programs are likely to have to pay for the treatment of patients who suffer complications after using mifepristone. The Republican states have said that they should also be allowed to stay in Texas, even without the original Plaintiffs. It would be inefficient for the case to be sent to another court following nearly two years of litigation.
A group of Democratic states has filed a separate lawsuit to stop the FDA from imposing further restrictions on Mifepristone.
After taking office in January 2017, it is unclear how Donald Trump, the Republican president-elect, will deal with mifepristone lawsuits and Kacsmaryk, the judge who was appointed by him during his first term. Trump stated during his election campaign that he wouldn’t ban the drug.